{"filings":[{"id":90694,"accession_number":"0001104659-26-057271","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tactile Systems shareholders approve director removal amendment, re-elect all directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to allow director removal consistent with Delaware law; 14.9M For, 0.9M Against.","All nine director nominees re-elected: Burke, Asbury, Dodd, Huggenberger, King, Pearson, Shafer, Volkart, Washington.","Ratified Grant Thornton LLP as independent auditor for FY2026 with 18.5M For, 0.1M Against, no broker non-votes.","Advisory vote approved named executive officer compensation with 15.4M For, 0.4M Against, 3.0M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90693,"accession_number":"0001104659-26-054869","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q1 revenue up 23% to $75.3M; net loss narrows to $1.8M; raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $75.3M (+23% YoY); lymphedema +23%, airway clearance +22%.","Net loss $1.8M ($0.08 per share) vs $3.0M loss in Q1 2025; gross margin 76.5% vs 74%.","Adjusted EBITDA $3.7M vs ($0.3M) loss a year ago.","Raised FY2026 revenue guidance to $360-368M (prev $357-365M); adj EBITDA reaffirmed at $49-51M.","Received FDA 510(k) clearance for next-gen AffloVest; acquired LymphaTech for lymphedema diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":75267000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100436,"accession_number":"0001104659-26-024981","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Andrea Pearson to Board of Directors effective March 9, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pearson joins board and serves on Compliance & Reimbursement and Nominating & Corporate Governance committees.","She will receive pro rata RSUs valued at $155,000 and annual cash retainers totaling $60,000 (board plus committees).","Pearson previously scaled DispatchHealth from 2 to 50+ markets, driving 30x revenue increase as Chief Growth Officer.","Board size fixed at nine directors following appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100435,"accession_number":"0001104659-26-016370","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical Q4 revenue up 21% to $103.6M; acquires LymphaTech for $6.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2025 revenue $103.6M (+21% YoY); net income $10.6M ($0.46 diluted EPS) vs $9.7M ($0.40) in Q4 2024.","Full year 2025 revenue $329.5M (+12% YoY); adjusted EBITDA $44.8M ($37.1M in 2024).","FY2026 guidance: revenue $357-365M (8-11% growth), adjusted EBITDA $49-51M.","Acquired LymphaTech for $6.8M upfront cash plus contingent milestones; adds 3D scanning for lymphedema.","Repaid $26.3M term loan; repurchased $26.5M stock at avg $12.36 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116756,"accession_number":"0001104659-25-105537","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Tactile Medical Q3 net income $8.2M, revenue up 17%; raises FY guidance and authorizes $25M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $85.8M (+17% YoY), net income $8.2M ($0.36 diluted EPS) vs $5.2M ($0.21) in Q3 2024.","Adjusted EBITDA $14.4M vs $10.7M YoY; gross margin 76% vs 75%.","Paid off $24M term loan, refinanced revolver to $40M; cash $66M.","Authorized $25M share buyback program through Nov 2027.","FY 2025 guidance raised: revenue $317-321M (prior $310-315M), adj. EBITDA $38-39.5M (prior $33-35M)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":225928000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133203,"accession_number":"0001558370-25-010096","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Systems Q2 revenue $78.9M (+7.8% YoY); net income $3.2M vs $4.3M; raises low-end of adj EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $78.9M, up 7.8% YoY, ahead of prior expectations; gross margin improved to 75% from 74%.","Net income $3.2M ($0.14 diluted EPS) vs $4.3M ($0.18) in Q2 2024; Adjusted EBITDA $7.7M vs $9.1M.","Airway clearance product line revenue surged 52% YoY; lymphedema product line grew 2%.","FY2025 revenue guidance narrowed to $310-315M (prior $309-315M); adj EBITDA guidance raised to $33-35M (prior $32-34M) but below FY2024 adj EBITDA of $37.1M.","Completed $30M share repurchase program; refinanced credit facility, increased revolver to $40M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":140173000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149822,"accession_number":"0001104659-25-046813","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 2025 Equity Incentive Plan with 1.85M new shares; all board nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 Equity Incentive Plan approved, authorizing up to 1,850,000 new shares of common stock.","All eight director nominees elected, including William Burke, Valerie Asbury, Sheri Dodd, and others.","Say-on-pay approved with 15.7M votes for (96% of votes cast); board sets future advisory votes annually.","Grant Thornton LLP ratified as independent auditor for 2025 with 18.9M votes for.","No further awards will be granted under the 2016 Equity Incentive Plan after approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149821,"accession_number":"0001558370-25-006292","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q1 revenue flat, net loss widens; lowers FY 2025 revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue $61.3M (+0.3% YoY); net loss $3.0M vs $2.2M loss in Q1 2024.","Adjusted EBITDA loss $0.3M vs positive $1.0M in prior-year quarter.","Lymphedema product sales -3% YoY; airway clearance +22% YoY.","FY 2025 revenue guidance lowered to $309-315M (prior $316-322M); EBITDA guidance cut to $32-34M from $35-37M.","Repurchased $10M of stock in Q1; $16.5M remaining under $30M buyback program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":61268000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168842,"accession_number":"0001558370-25-001095","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q4 rev $85.6M (+10%), net income $9.7M; guides FY25 rev $316-322M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $85.6M (+10% YoY); gross margin 75.2% vs 72.1% YoY.","Q4 net income $9.7M ($0.40 diluted EPS) vs $8.2M ($0.35) YoY.","FY2024 revenue $293.0M (+7%); net income $17.0M vs $28.5M in 2023.","Cash $94.4M at year-end, up from $61.0M; $26.5M remaining share repurchase authorization.","FY2025 revenue guidance $316-322M (8-10% growth); adjusted EBITDA $35-37M vs $37.1M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":292984000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168841,"accession_number":"0001104659-25-002876","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tactile Medical appoints Laura King to Board of Directors effective Jan 13, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laura King elected to Board; serves on Audit and Compliance & Reimbursement Committees.","King brings 22-year GE Healthcare tenure as President & CEO of Global Interventional Business.","Initial RSU grant valued at pro rata portion of $145,000, vesting earlier of one year or 2025 annual meeting.","Annual cash retainers: $50,000 board, $10,000 audit committee, $5,000 compliance committee.","King also co-founder & CEO of BiaCure; formerly led NeuWave Medical (acquired by J&J)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185956,"accession_number":"0001558370-24-014254","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Tactile Medical Q3 revenue up 5% to $73.1M; guides FY2024 $292-295M, authorizes $30M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $73.1M (+5% YoY); lymphedema +4%, airway clearance +10%.","Net income $5.2M ($0.21 diluted) vs $22.3M in Q3 2023; adjusted EBITDA $10.7M vs $7.7M.","Gross margin improved to 75.0% from 70.9%; operating expenses up 16%.","FY2024 revenue guidance narrowed to $292-295M (prior $293-298M; growth 6-8%).","Board authorized up to $30M share repurchase program through Oct 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":207399000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202527,"accession_number":"0001558370-24-010853","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tactile Medical Q2 revenue $73.2M (+7% YoY); lowers FY 2024 guidance to $293-298M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $73.2M, up 7% YoY; lymphedema product revenue +8%, airway clearance +2%.","Net income of $4.3M ($0.18 diluted EPS) vs net loss of $0.1M in Q2 2023; adjusted EBITDA $9.1M.","Full-year 2024 revenue guidance lowered to $293-298M (7-9% growth) from prior $300-305M (9-11%).","Appointed Sheri Dodd as President and CEO effective July 1, 2024; received 510(k) clearance for Nimbl system."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":134306000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202526,"accession_number":"0001104659-24-078098","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tactile Systems settles shareholder derivative lawsuit, agrees to governance reforms and $0.5M fee payment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Enters Stipulation of Settlement in derivative lawsuit Weaver v. Moen, dated June 6, 2024.","Agrees to adopt and maintain corporate governance reforms; no admission of liability.","Will pay approximately $0.5 million in attorneys' fees and expenses; service awards up to $7,500 each.","Settlement hearing set for August 28, 2024 before Judge Gregory B. Williams in Delaware District Court."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218670,"accession_number":"0001104659-24-059336","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tactile Systems stockholders approve officer exculpation amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Valerie Asbury with 17.8M votes for, 442k withheld.","Ratification of Grant Thornton LLP as independent auditor for 2024 passed with 20.7M for.","Advisory say-on-pay passed with 17.8M for, 419k against, 22.5k abstain.","Amendment to certificate of incorporation allowing officer exculpation approved (17.3M for, 913k against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218669,"accession_number":"0001558370-24-006794","cik":1027838,"company_name":"TACTILE SYSTEMS TECHNOLOGY INC","ticker":"TCMD","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TCMD Q1 revenue up 4% to $61.1M, net loss $2.2M; reaffirms FY2024 outlook; CEO transition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $61.1M (+4% YoY); lymphedema +5%, airway clearance -4%.","Net loss $2.2M ($0.09/diluted share) vs $1.9M loss in Q1 2023; adjusted EBITDA $1.0M vs $0.5M.","Reaffirmed FY2024 revenue guidance $300M-$305M (9-11% growth).","CEO Dan Reuvers retiring July 1, 2024; Sheri Dodd appointed President and CEO effective same date.","Cash $60.7M, debt $28.5M; completed enrollment of 235-patient Flexitouch Plus trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":61088000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":565485404.5865923,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}